$AMRS The positive is we aren't having issues selling what we are making once formulated. Which makes me feel good about producing 5400 tonnes next year. That equates to roughly $104M in product revenue next year. Assuming continued efficiencies and additional capacity, that same growth rate should be good into 2021. Which gives us $275M in recurring revenue. And $393M in 2022. There is room for upside here though. The CBD and Sweetener market both provide upside.